目的：立体定向放疗（SRT）在脑转移瘤（BM）中被广泛应用，尤其是在寡转移酶中。当务之急是开发新的预后评分，以根据特定原发肿瘤的预后因素预测脑转移的总生存期（OS）。
方法：共有一百九十七名患者参与训练队列，以制定新的预后评分来预测特定原发肿瘤的脑转移的总生存期（OS）。使用Cox回归模型证实了独立的预后因素。根据OS的临床预后因素，采用Cox比例风险模型进行评分。结果在另一个有56名参与者的队列中得到验证，以评估分数的表现。
结果：一百九十七例329例脑转移患者接受了SRT。对于NSCLC，重要的预后因素是颅外转移，靶向治疗和脑转移瘤的数量。对于胃肠道癌症，重要的预后因素是靶向治疗和脑转移瘤的数量.
结论：预后因子评分因组织学类型而异，可用于对选定的脑转移患者进行有效分层。
OBJECTIVE: Stereotactic radiotherapy (SRT) was widely used in brain metastases (BM), especially in oligometastases. It is imperative to develop a new prognostic score to predict the overall survival (OS) of brain metastases based on prognostic factors for specific primary tumors.
METHODS: One hundred and ninety-seven patients were involved in the training cohort to develop a new prognostic score to predict the overall survival (OS) of brain metastases for specific primary tumors. Independent prognostic factors were confirmed using a Cox regression model. The score was developed based on clinical prognostic factors of OS with Cox proportional hazards model. The result was validated in another cohort with 56 participants to evaluate the performance of the score.
RESULTS: One hundred and ninety-seven patients with 329 brain metastases received SRT. For NSCLC, the significant prognostic factors were extracranial metastases, target therapy and number of brain metastases. For gastrointestinal cancer, the significant prognostic factors were target therapy and number of brain metastases.
CONCLUSIONS: The prognostic factors scores were varied by the histologic types which can be used to efficiently stratify for selected patients with brain-metastasis.
